Form 4: Ralph Alvarez Acquires Eli Lilly Shares Through Directors' Deferral Plan

Director Ralph Alvarez acquired 15.828 shares of Eli Lilly & Co common stock at $742.35 per share through the Lilly Directors' Deferral Plan.

Summary

• On January 21, 2025, Ralph Alvarez, a director of Eli Lilly & Co, acquired 15.828 shares of common stock.
• The acquisition was made at a price of $742.35 per share.
• These shares were acquired through the Lilly Directors' Deferral Plan in lieu of cash compensation.
• Following the transaction, Alvarez directly owns 54,705.324 shares of Eli Lilly & Co.
• The acquired shares will be settled in shares of common stock following Alvarez's separation from service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a routine transaction indicating director's continued investment in the company.

Positives

• The acquisition reflects Alvarez's continued investment in Eli Lilly & Co.
• The use of the Directors' Deferral Plan allows for tax-efficient compensation.

Future Outlook

The acquired shares will be settled in shares of common stock following the reporting person's separation from service.

Industry Context

Director share acquisitions are common and can be seen as a positive signal, indicating confidence in the company's future performance. Deferral plans are also a common way to compensate directors in a tax-efficient manner.

Comparison to Industry Standards

• Director compensation packages often include stock options, restricted stock units, or deferred stock plans.
• The Lilly Directors' Deferral Plan is similar to those offered by other large pharmaceutical companies such as Pfizer and Johnson & Johnson, which aim to align director interests with shareholder value.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it signals director confidence.
• The deferral plan impacts the director's compensation structure.

Key Dates